MAPT and Alzheimer disease: CSF analysis for AD diagnosis primarily relies on measuring biomarkers, including amyloid-beta (Aβ), total tau (t-Tau), and phosphorylated tau (p-Tau) (Olsson et al., 2016; Paterson et al., 2018; Shaw et al., 2009).